* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:41:26 ON 13 NOV 2000

=> file registry

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 0.21 | 0.21 |

FILE 'REGISTRY' ENTERED AT 14:41:35 ON 13 NOV 2000
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.


STRUCTURE FILE UPDATES: 12 NOV 2000 HIGHEST RN 302542-21-8
DICTIONARY FILE UPDATES: 12 NOV 2000 HIGHEST RN 302542-21-8

TSCA INFORMATION NOW CURRENT THROUGH July 8, 2000

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT for details.

=> s wvq/sqsp

L1 4364 WVQ/SQSP

=> s kqk/sqsp

L2 21348 KQK/SQSP

=> s kqk/sqsp and sql<=30

COMMAND INTERRUPTED
If this message appears repeatedly, please notify the Help Desk.
Enter "HELP STN" for information on contacting the nearest STN Help Desk by telephone or via SEND in the STNMAIL file.

=> s wvq/sqsp and sql<=30

COMMAND INTERRUPTED
If this message appears repeatedly, please notify the Help Desk.
Enter "HELP STN" for information on contacting the nearest STN Help Desk by telephone or via SEND in the STNMAIL file.

=> help stn

For additional assistance with system features and files, you may contact the STN Help Desk at the nearest STN Service Center.

In USA and Canada:

STN International
Chemical Abstracts Service
PO Box 02228
Columbus, OH 43202 USA

Phone: 800-848-6533
614-447-3698
800-848-6538 (in Ohio and Canada)

Hours: 8:00 am to 8:00 pm
US Eastern Time
Telex: 6842086 CHMAB
Telefax: 614-447-3798
STNmail: HLPDESKC
E-mail: help@cas.org

In Europe:

STN International
FIZ Karlsruhe
Postfach 2465
D-76012 Karlsruhe
Germany

Phone: (+49)-7247/808-555
Hours: 7:30 am to 6:00 pm
Central European Time
Telex: 17724710+
Telefax: (+49) 7247/808-259
STNmail: HLPDESKK
E-mail: hlpdeskk@fiz-karlsruhe.de

In Japan:

STN International
c/o Japan Science and Technology
Corporation (JST)
5-3 Yonbancho, Chiyoda-ku
Tokyo 102-0081, Japan

Phone: (+81) 3-5214-8414
Toll free: 0120-521022
(in Japan Only)
Hours: 9:00 am to 5:00 pm
Japan Time
Telefax: (+81) 3-5214-8410
STNmail: HLPDESKT
E-mail: helpdesk@mr.jst.go.jp
http:www://jst.go.jp/

You may use the SEND command in the STNMAIL File to contact any Service Center. If you want a particular Center to contact you, be sure to include that information in your message.

```
=> s sql<=30

L3      708565 SQL<=30

=> s kqk/sqsp and sql<=30

           538 KQK/SQSP
        708565 SQL<=30
L4         538 KQK/SQSP AND SQL<=30

=> s wvq/sqsp and sql<=30

COMMAND INTERRUPTED
If this message appears repeatedly, please notify the Help Desk.
Enter "HELP STN" for information on contacting the nearest STN Help
Desk by telephone or via SEND in the STNMAIL file.

=> s wvq/sqsp and sql<=20

COMMAND INTERRUPTED
If this message appears repeatedly, please notify the Help Desk.
Enter "HELP STN" for information on contacting the nearest STN Help
Desk by telephone or via SEND in the STNMAIL file.

=> file caplus

COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               84.60      84.81

FILE 'CAPLUS' ENTERED AT 14:50:19 ON 13 NOV 2000
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1967 - 13 Nov 2000 VOL 133 ISS 21
FILE LAST UPDATED: 12 Nov 2000 (20001112/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

Now you can extend your author, patent assignee, patent information, and title searches back to 1907. The records from 1907-1966 now have this searchable data in CAOLD. You now have electronic access to all of CA: 1907 to 1966 in CAOLD and 1967 to the present in CAPLUS on STN.

```
=> d his


     (FILE 'HOME' ENTERED AT 14:41:26 ON 13 NOV 2000)

     FILE 'REGISTRY' ENTERED AT 14:41:35 ON 13 NOV 2000
L1          4364 S WVQ/SQSP
L2         21348 S KQK/SQSP
L3        708565 S SQL<=30
L4           538 S KQK/SQSP AND SQL<=30

     FILE 'CAPLUS' ENTERED AT 14:50:19 ON 13 NOV 2000

=> s l4

L5          279 L4

=> dup rem l5

PROCESSING COMPLETED FOR L5
L6          279 DUP REM L5 (0 DUPLICATES REMOVED)

=> l6 and chemokine

L6 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l6 and chemokine

L7          279 S L6
           5648 CHEMOKINE
           4785 CHEMOKINES
           6703 CHEMOKINE
                  (CHEMOKINE OR CHEMOKINES)
L8            6 L7 AND CHEMOKINE

=> d l8 total ibib kwic


L8   ANSWER 1 OF 6  CAPLUS  COPYRIGHT 2000 ACS
ACCESSION NUMBER:         2000:493573  CAPLUS
DOCUMENT NUMBER:          133:134180
```

TITLE: Compounds and methods to inhibit or augment an inflammatory response

INVENTOR(S): Grainger, David J.; Tatalick, Lauren Marie

PATENT ASSIGNEE(S): Neorx Corporation, USA

SOURCE: PCT Int. Appl., 387 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2000042071 | A2 | 20000720 | WO 2000-US821 | 20000112 |

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

| | |
|---|---|
| US 1999-229071 | 19990112 |
| US 1999-271192 | 19990317 |
| US 1999-452406 | 19991201 |

OTHER SOURCE(S): MARPAT 133:134180

AB Isolated and purified **chemokine** peptides, variants, and derivs. thereof, as well as **chemokine** peptide analogs, are provided. The **chemokine** peptide 3 derivs. are useful for preventing or treating diseases assocd. with recruitment of hematopoietic cells, and histamine release from basophils or mast cells; stroke; vascular disease (e.g. coronary artery disease, myocardial infarction, unstable angina pectoris, atherosclerosis or vasculitis); low bone mineral d.; autoimmune diseases; tumor; psoriasis; wound healing; asthma; organ transplant rejection; rheumatoid arthritis; allergy; inhibition of antigen-induced recall response; lentivirus infection or HIV infection; and parasitic or malaria infection.

ST **chemokine** peptide 3 agonist antagonist inflammation

IT **Chemokines**
RL: BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(3 peptide; **chemokine** 3 peptide analogs for treating inflammatory diseases)

IT Blood-group substances
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Duffy; **chemokine** 3 peptide analogs for treating inflammatory diseases)

IT **Chemokines**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(SDF-1 (stromal-derived factor-1); **chemokine** 3 peptide analogs for treating inflammatory diseases)

IT Heart, disease
(angina pectoris, unstable; **chemokine** 3 peptide analogs for treating inflammatory diseases)

IT Organic compounds, biological studies
RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(biol.; **chemokine** 3 peptide analogs for treating inflammatory diseases)

IT Mineral elements, biological studies
RL: ADV (Adverse effect, including toxicity); BSU (Biological study,

unclassified); BIOL (Biological study)
(bone, low d.; **chemokine** 3 peptide analogs for treating inflammatory diseases)

IT Allergy
Antitumor agents
Antiviral agents
Asthma
Atherosclerosis
Autoimmune disease
Basophil
Blood vessel, disease
Erythrocyte
Immunostimulation
Immunotherapy
Indicators
Inflammation
Mast cell
Protein sequences
Psoriasis
Rheumatoid arthritis
Transplant rejection
Vaccines
Vertebrate (Vertebrata)
Wound healing
(**chemokine** 3 peptide analogs for treating inflammatory diseases)

IT Immunoglobulins
Interleukin 4
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(**chemokine** 3 peptide analogs for treating inflammatory diseases)

IT Tumor necrosis factors
RL: BOC (Biological occurrence); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(**chemokine** 3 peptide analogs for treating inflammatory diseases)

IT **Chemokine** receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(**chemokine** 3 peptide analogs for treating inflammatory diseases)

IT Antigens
Interleukin 8
Leukotrienes
Macrophage inflammatory protein 1.alpha.
Macrophage inflammatory protein 1.beta.
Monocyte chemoattractant protein-1
Prostaglandins
Thromboxanes
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**chemokine** 3 peptide analogs for treating inflammatory diseases)

IT Neutrophil-activating peptide-2
Peptides, biological studies
Proteins, general, biological studies
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**chemokine** 3 peptide analogs for treating inflammatory diseases)

IT Disease, animal
(**chemokine** activity-assocd.; **chemokine** 3 peptide analogs for treating inflammatory diseases)

IT Carbohydrates, biological studies
Monosaccharides
Polysaccharides, biological studies

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**chemokine** peptide conjugate; **chemokine** 3 peptide analogs for treating inflammatory diseases)

IT Artery, disease
(coronary; **chemokine** 3 peptide analogs for treating inflammatory diseases)

IT Immunity
(immunol. memory, recall; **chemokine** 3 peptide analogs for treating inflammatory diseases)

IT Heart, disease
(infarction; **chemokine** 3 peptide analogs for treating inflammatory diseases)

IT Human immunodeficiency virus
Lentivirus
Malaria
Parasite
(infection; **chemokine** 3 peptide analogs for treating inflammatory diseases)

IT Bone, disease
(low d.; **chemokine** 3 peptide analogs for treating inflammatory diseases)

IT Bone
(minerals, low d.; **chemokine** 3 peptide analogs for treating inflammatory diseases)

IT **Chemokines**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(monocyte chemoattractant protein 3; **chemokine** 3 peptide analogs for treating inflammatory diseases)

IT **Chemokines**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(monocyte chemoattractant protein-2; **chemokine** 3 peptide analogs for treating inflammatory diseases)

IT Hematopoietic precursor cell
(recruitment; **chemokine** 3 peptide analogs for treating inflammatory diseases)

IT Brain, disease
(stroke; **chemokine** 3 peptide analogs for treating inflammatory diseases)

IT Blood vessel, disease
(vasculitis; **chemokine** 3 peptide analogs for treating inflammatory diseases)

IT 51-45-6, Histamine, biological studies
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(**chemokine** 3 peptide analogs for treating inflammatory diseases)

IT 506-32-1, Arachidonic acid
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**chemokine** 3 peptide analogs for treating inflammatory diseases)

IT 3062-07-5 4685-12-5 13184-14-0 24613-12-5 35193-18-1 36301-96-9
38579-27-0 51790-17-1 54532-75-1 54925-87-0 54944-27-3
56395-09-6 57625-86-2 57625-90-8 66138-71-4 85807-09-6
106325-99-9 106326-00-5 106326-01-6 106326-02-7 106326-71-0
114148-97-9 114991-28-5 115416-08-5 130036-94-1 146436-61-5
147841-68-7 151367-92-9 155575-02-3 175176-05-3 180511-27-7
193413-93-3 **221172-52-7** **221172-53-8** 221172-54-9
**221172-55-0** **221172-56-1** 221172-57-2
**221172-58-3** **221172-59-4** **221172-61-8**
**221172-62-9** 221172-63-0 221172-64-1 221172-65-2
221172-67-4 221172-69-6 221172-71-0 **221172-73-2**
**221172-74-3** **221172-75-4** 221172-76-5 221172-78-7
221172-80-1 **221172-81-2** **221172-82-3**
**221172-83-4** 221172-84-5 221172-85-6 221172-86-7
221172-87-8 221172-89-0 221172-91-4 221172-95-8 221172-96-9

221173-06-4 221173-07-5 243662-32-0 248585-56-0 284495-25-6
284495-26-7 284495-27-8 **284495-28-9 284495-29-0**
**284495-30-3D**, biotinylated 284495-34-7 284495-36-9
**284495-37-0** 284495-38-1 284495-39-2 284495-40-5
**284495-41-6** 284495-42-7 **284495-43-8**
**284495-45-0** 284495-46-1 284495-47-2 284495-49-4
284495-50-7 284495-51-8 284495-52-9 284495-53-0 284495-54-1
**284495-55-2 284495-56-3 284495-57-4**
**284495-58-5 284495-59-6D**, biotinylated 284495-60-9
284495-61-0 284495-62-1 284495-62-1D, biotinylated 284495-63-2
284495-64-3 284495-65-4D, biotinylated 284495-66-5 284495-68-7
284495-69-8 284495-70-1 284495-71-2 284677-98-1
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**chemokine** 3 peptide analogs for treating inflammatory diseases)

IT 50-99-7, D-Glucose, biological studies
RL: BSU (Biological study, unclassified); RCT (Reactant); BIOL (Biological study)
(**chemokine** 3 peptide analogs for treating inflammatory diseases)

IT 24196-29-0P 284495-33-6P
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**chemokine** 3 peptide analogs for treating inflammatory diseases)

IT 9004-10-8, Insulin, biological studies 12629-01-5, Human growth hormone
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**chemokine** 3 peptide analogs for treating inflammatory diseases)

IT 284495-31-4P
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**chemokine** 3 peptide analogs for treating inflammatory diseases)

IT 56-85-9, L-Glutamine, reactions 82-58-6, Lysergic acid 38460-95-6, 10-Undecenoyl chloride 128625-52-5, PyBOP 284495-32-5
RL: RCT (Reactant)
(**chemokine** 3 peptide analogs for treating inflammatory diseases)

IT 54350-44-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(**chemokine** 3 peptide analogs for treating inflammatory diseases)

IT 102619-57-8, Lymphokine MIP 1.alpha. (human clone pLD78 macrophage inflammatory precursor reduced) 111366-43-9, Interleukin 8 (human clone 3-10C precursor reduced) 113755-98-9, Melanoma growth stimulatory activity (human isoform .alpha. precursor reduced) 118366-81-7, Lymphokine MCP 1 (mouse clone .lambda.JE-1 precursor protein moiety reduced) 122318-61-0, Lymphokine MIP 1.beta. (human clone pAc-Act2 macrophage inflammatory precursor reduced) 124147-40-6, Lymphokine MCP 1
(human precursor protein moiety reduced) 125267-37-0 128002-31-3, Protein I 309 (human clone MB5-2 precursor reduced) 130938-43-1, Cytokine CRG 2 (mouse clone 1.1-1 precursor reduced) 131201-04-2, Lymphokine MIP 2.alpha. (human clone hMIP-2-5a macrophage inflammatory precursor reduced) 147855-88-7, Monokine (human clone H-1-3 gene mig interferon .gamma.-inducible precursor reduced) 158132-79-7 161348-23-8 163548-48-9 163548-49-0, Lymphokine (human gene RANTES fragment) 167616-16-2 167616-19-5 168257-03-2 175138-24-6, Eotaxin
(human clone 25 precursor) 177404-40-9, **Chemokine** .beta.-10

(human precursor) 286026-09-3 286370-36-3
RL: PRP (Properties)
(unclaimed protein sequence; compds. and methods to inhibit or augment an inflammatory response)

IT 284495-35-8 284495-48-3 284495-67-6
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(unclaimed sequence; **chemokine** 3 peptide analogs for treating inflammatory diseases)

IT 70364-88-4 134365-65-4 162290-78-0 162559-42-4 167871-05-8
**221172-72-1** 221172-77-6 221172-79-8 221172-98-1
221172-99-2 221173-00-8 221173-01-9 221173-02-0 221173-03-1
221173-04-2 286000-61-1 286000-62-2 286000-63-3 286000-64-4
286000-65-5 286000-66-6 286000-67-7 286000-68-8 286000-69-9
286000-71-3 286000-72-4 286000-74-6 286000-76-8 286000-78-0
286000-80-4 286000-82-6 286000-84-8 286000-86-0 286000-88-2
286000-90-6 286000-92-8 286000-94-0 286000-95-1 **286001-03-4**
286001-04-5 286001-05-6
RL: PRP (Properties)
(unclaimed sequence; compds. and methods to inhibit or augment an inflammatory response)

L8 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2000 ACS
ACCESSION NUMBER: 2000:47964 CAPLUS
DOCUMENT NUMBER: 132:273746
TITLE: Quantitative Analysis of a Synthetic Peptide, NR58-3.14.3, in Serum by LC-MS with Inclusion of a Diastereomer as Internal Standard
AUTHOR(S): Wilbert, Sibylle M.; Engrissei, Gina; Yau, Eric K.; Grainger, David J.; Tatalick, Lauren; Axworthy, Don B.
CORPORATE SOURCE: NeoRx Corporation, Seattle, WA, 98119-4007, USA
SOURCE: Anal. Biochem. (2000), 278(1), 14-21
CODEN: ANBCA2; ISSN: 0003-2697
PUBLISHER: Academic Press
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 17
REFERENCE(S):
(1) Allievi, C; Rapid Commun Mass Spectrom 1998, V12, P33 CAPLUS
(2) Carrascal, M; J Pharm Bio Anal 1998, V17, P1129 CAPLUS
(3) Clarke, N; FEBS Lett 1998, V430, P419 CAPLUS
(6) Jameson, B; Nature 1994, V368, P744 CAPLUS
(7) Kikuchi, K; J Mass Spectrom 1999, V34, P93 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

ST peptide synthetic **chemokine** pharmacokinetics blood LC MS internal std

IT **Chemokines**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(quant. anal. of a synthetic peptide, NR58-3.14.3, in serum by LC-MS with inclusion of a diastereomer as internal std.)

IT **263771-13-7P**
RL: ANT (Analyte); BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); ANST (Analytical study); BIOL (Biological study); PREP (Preparation)
(synthetic, NR58-3.14.3; quant. anal. of a synthetic peptide, NR58-3.14.3, in serum by LC-MS with inclusion of a diastereomer as internal std.)

IT **263771-14-8P**
RL: ARU (Analytical role, unclassified); SPN (Synthetic preparation); ANST (Analytical study); PREP (Preparation)
(synthetic, NR58-3.14.5; quant. anal. of a synthetic peptide, NR58-3.14.3, in serum by LC-MS with inclusion of a diastereomer as internal std.)

L8 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2000 ACS
ACCESSION NUMBER: 1999:819270 CAPLUS
DOCUMENT NUMBER: 132:69369
TITLE: Compositions and methods for delivery of agents for altering neuronal growth, regeneration, and survival
INVENTOR(S): Baird, Andrew; Berry, Martin; Logan, Ann; Gonzalez, Ana Maria
PATENT ASSIGNEE(S): Selective Genetics, Inc., USA
SOURCE: PCT Int. Appl., 128 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9966959 | A2 | 19991229 | WO 1999-US12126 | 19990601 |
| WO 9966959 | A3 | 20000504 | | |

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

| | | | | |
|---|---|---|---|---|
| AU 9962380 | A1 | 20000110 | AU 1999-62380 | 19990601 |
| PRIORITY APPLN. INFO.: | | | US 1998-88419 | 19980601 |
| | | | US 1998-178286 | 19981023 |
| | | | WO 1999-US12126 | 19990601 |

IT **Chemokines**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CXC family; gene therapy and delivery of agents for altering neuronal growth, regeneration, and survival)

IT **Chemokines**
RL: BAC (Biological activity or effector, except adverse); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(ENA-78; gene therapy and delivery of agents for altering neuronal growth, regeneration, and survival)

IT 113516-56-6 132328-28-0 152551-92-3 202601-31-8 205385-47-3
244050-78-0 253328-14-2 253328-15-3 253328-16-4 253328-17-5
253328-19-7 253328-21-1 **253328-22-2** 253328-23-3
**253328-24-4** 253328-25-5 253328-26-6 253328-27-7
253328-28-8 253328-29-9 253328-30-2
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(gene therapy and delivery of agents for altering neuronal growth, regeneration, and survival)

L8 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2000 ACS
ACCESSION NUMBER: 1999:477233 CAPLUS
DOCUMENT NUMBER: 131:270612
TITLE: Cellular and humoral mechanisms of vascularized allograft rejection induced by indirect recognition of donor MHC allopeptides
AUTHOR(S): Vella, John P.; Magee, Colm; Vos, Lydia; Womer, Karl; Rennke, Helmut; Carpenter, Charles B.; Hancock, Wayne;

Sayegh, Mohamed H.
CORPORATE SOURCE: Laboratory of Immunogenetics and Transplantation, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA
SOURCE: Transplantation (1999), 67(12), 1523-1532
CODEN: TRPLAU; ISSN: 0041-1337
PUBLISHER: Lippincott Williams & Wilkins
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 43
REFERENCE(S):
(2) Auchincloss, H; Proc Natl Acad Sci USA 1993, V90(8), P3373 CAPLUS
(3) Benham, A; Transplantation 1994, V58(11), P1236 CAPLUS
(5) Benichou, G; Immunol Today 1997, V18, P67 CAPLUS
(6) Benichou, G; J Exp Med 1992, V175, P305 CAPLUS
(8) Chandraker, A; J Clin Invest 1998, V101(11), P2309 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

AB To investigate the role and mechanisms of indirect allorecognition in allograft rejection, we studied whether priming T cells with donor-derived MHC allopeptides could accelerate rejection in a vascularized allograft model. Lewis recipients of fully mismatched Wistar Furth cardiac allografts were immunized before transplantation with donor MHC allopeptides. Animals immunized with immunogenic class II MHC allopeptides rejected their grafts in a significantly accelerated fashion compared with controls. Addnl. studies demonstrated that a single immunodominant RT1.D (HLA-DR like) allopeptide was responsible for accelerating the rejection process. Histol. anal. of rejected allografts revealed marked vascular rejection in the accelerated, although not the control, group as well as severe cellular rejection. Peak prodn. of IgM and IgG donor-specific alloantibodies was detected by flow cytometry 1 wk earlier in the sera of the accelerated group compared with the control group. Immunohistol. anal. of grafts from the accelerated compared with the control group showed increased endothelial deposition of IgG2b, C3, and fibrin, and up-regulation of class II MHC mol. expression. Increased intragraft expression of interferon-.gamma. and the interferon-.gamma.-induced **chemokines**, inducible protein-10 and Mig, and infiltration by activated mononuclear cells expressing CXCR3, the receptor for inducible protein-10 and Mig, was also seen. These novel data provide evidence of a definitive link between indirect allorecognition of donor-derived MHC class II peptides and the cellular and humoral mechanisms of vascularized allograft rejection.

IT 152684-06-5P 152684-08-7P 152684-11-2P 187099-83-8P 187099-84-9P 245663-46-1P 245663-47-2P **245663-48-3P**
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
(cellular and humoral mechanisms of vascularized allograft rejection induced by indirect recognition of donor MHC allopeptides in rat)

L8 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2000 ACS
ACCESSION NUMBER: 1999:443132 CAPLUS
DOCUMENT NUMBER: 131:208594
TITLE: Identification of oligopeptide sequences which inhibit migration induced by a wide range of **chemokines**
AUTHOR(S): Reckless, Jill; Grainger, David J.
CORPORATE SOURCE: Department of Medicine, Addenbrookes Hospital, University of Cambridge, Cambridge, CB2 2QQ, UK
SOURCE: Biochem. J. (1999), 340(3), 803-811

CODEN: BIJOAK; ISSN: 0264-6021
PUBLISHER: Portland Press Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 32
REFERENCE(S):
(1) Ahuja, S; Immunol Today 1994, V15, P281 CAPLUS
(2) Bleul, C; Nature (London) 1996, V382, P829 CAPLUS
(3) Brown, Z; J Leukocyte Biol 1996, V59, P75 CAPLUS
(4) Cocchi, F; Science 1995, V270, P1811 CAPLUS
(5) Conti, P; Blood 1997, V89, P4120 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

TI Identification of oligopeptide sequences which inhibit migration induced by a wide range of **chemokines**

AB The authors have identified an amino acid sequence, termed peptide 3, corresponding to amino acids 51-62 of the mature human monocyte chemoattractant protein-1 (MCP-1), which inhibits human mononuclear-cell and THP-1-cell migration induced by a wide range of **chemokines**. For example, peptide 3 inhibited MCP-1-induced THP-1 migration in a transwell assay with an ED50 of approx. 8.mu.M. Peptide 3 binds directly to THP-1 cells with an assocn. const. of approx. 10.mu.M, and is therefore likely to be a direct receptor antagonist for CC and CXC **chemokine** receptors. By performing a structure-function anal. of this peptide, the authors have identified a sequence variant that shows an approx. 3-4-fold greater potency as an inhibitor of **chemokine**-induced migration [Leu4Ile11 peptide 3 (1-12)]. Furthermore, unlike peptide 3, which binds to the Duffy antigen receptor for **chemokines** on human erythrocytes with a similar affinity to the specific **chemokine** receptors on THP-1 cells, the Leu4Ile11 peptide 3 (1-12) sequence variant shows at least 20-fold greater selectivity for the specific receptors. Derivs. of Leu4Ile11 peptide 3 (1-12) are therefore the best candidates among the mols. the authors have investigated for use as a **chemokine** inhibitor in vivo.

ST oligopeptide sequence mononuclear cell migration **chemokine**

IT **Chemokines**
(C-X-C, stromal cell-derived factor-1.alpha.; identification of oligopeptide sequences which inhibit migration of mononuclear cells induced by a wide range of **chemokines** in relation to mediation by **chemokine** receptors)

IT Mononuclear cell (leukocyte)
(identification of oligopeptide sequences which inhibit migration of mononuclear cells induced by a wide range of **chemokines** in relation to mediation by **chemokine** receptors)

IT Interleukin 8
Macrophage inflammatory protein 1.alpha.
Monocyte chemoattractant protein-1
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BIOL (Biological study); PROC (Process)
(identification of oligopeptide sequences which inhibit migration of mononuclear cells induced by a wide range of **chemokines** in relation to mediation by **chemokine** receptors)

IT **Chemokine** receptors
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(identification of oligopeptide sequences which inhibit migration of mononuclear cells induced by a wide range of **chemokines** in relation to mediation by **chemokine** receptors)

IT Structure-activity relationship
(leukocyte migration-inhibiting; identification of oligopeptide sequences which inhibit migration of mononuclear cells induced by a wide range of **chemokines** in relation to mediation by **chemokine** receptors)

IT Cell migration
(leukocyte; identification of oligopeptide sequences which inhibit migration of mononuclear cells induced by a wide range of **chemokines** in relation to mediation by **chemokine**

receptors)

IT **221172-52-7P 221172-53-8P** 221172-54-9P
**221172-55-0P 221172-56-1P** 221172-57-2P
**221172-58-3P 221172-59-4P** 221172-87-8P 243662-32-0P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(identification of oligopeptide sequences which inhibit migration of mononuclear cells induced by a wide range of **chemokines** in relation to mediation by **chemokine** receptors)

L8 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2000 ACS
ACCESSION NUMBER: 1999:194178 CAPLUS
DOCUMENT NUMBER: 130:236476
TITLE: **Chemokine**-derived peptides, peptide variants, derivatives and analogs for modulation of inflammatory responses
INVENTOR(S): Grainger, David J.; Tatalick, Lauren Marie; Kanaly, Suzanne T.
PATENT ASSIGNEE(S): Neorx Corporation, USA
SOURCE: PCT Int. Appl., 208 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9912968 | A2 | 19990318 | WO 1998-US19052 | 19980911 |
| WO 9912968 | A3 | 19990729 | | |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 9893153 | A1 | 19990329 | AU 1998-93153 | 19980911 |
| EP 1012187 | A2 | 20000628 | EP 1998-946057 | 19980911 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| PRIORITY APPLN. INFO.: | | | US 1997-927939 | 19970911 |
| | | | WO 1998-US19052 | 19980911 |

TI **Chemokine**-derived peptides, peptide variants, derivatives and analogs for modulation of inflammatory responses

AB The authors disclose the identification and characterization of **chemokine**-derived peptides, substituted variants and isosteres, and peptidic mimics that exhibit agonistic and antagonistic activity for **chemokine** receptors. In one example, a peptide derived from a conserved region of human monocyte chemoattractant protein-1 (MCP-1) was shown to inhibit the migration of the THP-1 cell line in response to MIP-1.alpha., MCP-1, SDF-1.alpha., and IL-8. Thus, inhibition was both specific and general. In addn., cyclic and reverse D-enantiomeric analogs of the peptide exhibited improved antagonistic activity. In a second example, a peptide derived from a non-conserved portion of MCP-1 was shown to inhibit CXCR4-mediated infection of Jurkat cells by HIV.

ST **chemokine** peptide antiinflammatory

IT C-C **chemokines**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CK.beta.8; agonistic and antagonistic activity of peptides, peptide variants, derivs. and analogs of)

IT Blood groups

RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(Duffy; **chemokine**-derived peptides, peptide variants, derivs. and analogs as antagonists of ligands for)

IT C-X-C **chemokines**
(ENA78; agonistic and antagonistic activity of peptides, peptide variants, derivs. and analogs of)

IT C-X-C **chemokines**
(GRO.gamma.; agonistic and antagonistic activity of peptides, peptide variants, derivs. and analogs of)

IT C-C **chemokines**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HCC-1; agonistic and antagonistic activity of peptides, peptide variants, derivs. and analogs of)

IT C-C **chemokines**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(I309; agonistic and antagonistic activity of peptides, peptide variants, derivs. and analogs of)

IT C-C **chemokines**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(LARC; agonistic and antagonistic activity of peptides, peptide variants, derivs. and analogs of)

IT C-X-C **chemokines**
(SDF-1; agonistic and antagonistic activity of peptides, peptide variants, derivs. and analogs of)

IT C-C **chemokines**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TARC; agonistic and antagonistic activity of peptides, peptide variants, derivs. and analogs of)

IT C-X-C **chemokines**
(agonistic and antagonistic activity of peptides, peptide variants, derivs. and analogs of)

IT Eotaxin
Interferon inducible protein IP-10
Interleukin 8
MGSA **chemokine**
Macrophage inflammatory protein 1.alpha.
Macrophage inflammatory protein 1.beta.
Monocyte chemoattractant protein-1
Neutrophil-activating peptide-2
RANTES (**chemokine**)
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(agonistic and antagonistic activity of peptides, peptide variants, derivs. and analogs of)

IT C-C **chemokines**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(agonistic and antagonistic activity of peptides, peptide variants, derivs. and analogs of)

IT Peptidomimetics
(as **chemokine** agonists and antagonists)

IT Pseudopeptides
Tripeptides
RL: BAC (Biological activity or effector, except adverse); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as **chemokine** agonists and antagonists)

IT Adjuvants (immunological)
(**chemokine**-derived peptides, peptide variants, derivs. and analogs)

IT Anti-AIDS drugs
Anti-ischemic agents
Antianginal agents
Antiasthmatics
Antiatherosclerotics
Antihypertensives
Antimalarials
Antiosteoporotic agents
Antirheumatic drugs

Antitumor agents
Antiviral agents
Contraceptives
Parasiticides
Tuberculostatics
(**chemokine**-derived peptides, peptide variants, derivs. and analogs as)

IT **Chemokine** receptors
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(**chemokine**-derived peptides, peptide variants, derivs. and analogs as antagonists of)

IT Allergy inhibitors
T cell infection
Transplant rejection
(**chemokine**-derived peptides, peptide variants, derivs. and analogs as inhibitors of)

IT Lentivirus
(**chemokine**-derived peptides, peptide variants, derivs. and analogs as inhibitors of infection by)

IT Tumor necrosis factor .alpha.
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(**chemokine**-derived peptides, peptide variants, derivs. and analogs as inhibitors of inflammatory response to)

IT Leukotrienes
Prostaglandins
Thromboxanes
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(**chemokine**-derived peptides, peptide variants, derivs. and analogs as inhibitors of metab. of)

IT Wound healing (animal)
(**chemokine**-derived peptides, peptide variants, derivs. and analogs for)

IT Leukocyte infiltration
Mast cell degranulation
(**chemokine**-derived peptides, peptide variants, derivs. and analogs for inhibition of)

IT Vaccines
(**chemokine**-derived peptides, peptide variants, derivs. and analogs in)

IT Basophil
(degranulation; **chemokine**-derived peptides, peptide variants, derivs. and analogs for inhibition of)

IT Cytokines
RL: BAC (Biological activity or effector, except adverse); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors, **chemokine** inhibitors; **chemokine**-derived peptides, peptide variants, derivs. and analogs as)

IT Autoimmune diseases
Endotoxemia
Psoriasis
Vasculitis
(inhibitors; **chemokine**-derived peptides, peptide variants, derivs. and analogs as)

IT C-C **chemokines**
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(monocyte chemoattractant protein 3; agonistic and antagonistic activity of peptides, peptide variants, derivs. and analogs of)

IT C-C **chemokines**
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(monocyte chemoattractant protein-2; agonistic and antagonistic activity of peptides, peptide variants, derivs. and analogs of)

IT Peptides, biological studies
RL: BAC (Biological activity or effector, except adverse); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(retro-inverso; as **chemokine** agonists and antagonists)

IT Myocardial infarction

(therapeutic agents; **chemokine**-derived peptides, peptide variants, derivs. and analogs as)

IT **221172-52-7**
RL: BAC (Biological activity or effector, except adverse); PRP (Properties); BIOL (Biological study)
(agonist and antagonist activity of **chemokine**-derived peptides, peptide variants, derivs. and analogs)

IT 13184-14-0 54532-75-1 57625-86-2 106326-00-5 **221172-53-8**
221172-54-9 **221172-55-0** **221172-56-1** 221172-57-2
**221172-58-3** **221172-59-4** **221172-60-7**
**221172-61-8** **221172-62-9** 221172-63-0 221172-64-1
221172-65-2 221172-66-3 221172-67-4 221172-68-5 221172-69-6
221172-70-9 221172-71-0 **221172-72-1** **221172-73-2**
**221172-74-3** **221172-75-4** 221172-76-5 221172-77-6
221172-78-7 221172-79-8 221172-80-1 **221172-81-2**
**221172-82-3** **221172-83-4** 221172-84-5 221172-85-6
221172-86-7 221172-87-8 221172-88-9 221172-89-0 221172-90-3
221172-91-4 221172-92-5 221172-95-8 221172-96-9 221172-97-0
221172-98-1 221172-99-2 221173-00-8 221173-01-9 221173-02-0
221173-03-1 221173-04-2 221173-05-3 221173-06-4 221173-07-5
221173-47-3 221173-48-4
RL: BAC (Biological activity or effector, except adverse); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(agonist and antagonist activity of **chemokine**-derived peptides, peptide variants, derivs. and analogs)

IT 108-94-1D, Cyclohexanone, derivs.
RL: PRP (Properties)
(agonist and antagonist activity of **chemokine**-derived peptides, peptide variants, derivs. and analogs)

IT 221197-23-5P, Trypilamine
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(as **chemokine** antagonist)

IT 506-32-1, Arachidonic acid
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(**chemokine**-derived peptides, peptide variants, derivs. and analogs as inhibitors of metab. of)

=> s l7 and inhibitor

329026 INHIBITOR
351160 INHIBITORS
536944 INHIBITOR
(INHIBITOR OR INHIBITORS)
L9 26 L7 AND INHIBITOR

=> d l9 total

L9 ANSWER 1 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 2000:628260 CAPLUS
DN 133:221613
TI Site-specific mutated allergens for decreased clinical reaction to allergy
IN Bannon, Gary A.; Burks, A. Wesley, Jr.; Sampson, Hugh A.; Sosin, Howard B.; King, Nina E.; Maleki, Soheila J.; Connaughton, Cathie; Kopper, Randall A.; Rabjohn, Patrick A.; Shin, David S.; Compadre, Cesar M.
PA The Board of Trustees of the University of Arkansas, USA; Mount Sinai School of Medicine of New York University
SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 2000052154 | A2 | 20000908 | WO 2000-US5487 | 20000302 |

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1999-122566 19990302
US 1999-122960 19990303
US 1999-267719 19990311
US 2000-494096 20000128

L9 ANSWER 2 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 2000:609013 CAPLUS
DN 133:205085
TI High throughput assay for protein modification
IN Colyer, John; Craig, Roger Kingdon; Maschio, Antonio; Mezna, Mokdad
PA Fluorescience Limited, UK
SO PCT Int. Appl., 128 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 6

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 2000050902 | A2 | 20000831 | WO 2000-GB669 | 20000225 |

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI GB 1999-4398 19990225

L9 ANSWER 3 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 2000:351544 CAPLUS
DN 133:9081
TI Modified and truncated penetratin derivatives as membrane translocation carriers for drug transport
IN Fischer, M. Peter; Zhelev, Nikolai
PA Cyclacel Limited, UK
SO PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 2000029427 | A2 | 20000525 | WO 1999-GB3750 | 19991111 |
| | WO 2000029427 | A3 | 20001005 | | |

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,

CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
GB 2346616 A1 20000816 GB 1999-26719 19991111
PRAI GB 1998-25000 19981113
GB 1998-25001 19981113
GB 1999-2522 19990204
GB 1999-2525 19990204
GB 1999-14578 19990622

L9 ANSWER 4 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 2000:291095 CAPLUS
DN 132:329919
TI Modified peptides containing an antibody Fc domain as therapeutic agents
IN Feige, Ulrich; Liu, Chuan-fa; Cheetham, Janet; Boone, Thomas Charles
PA Amgen Inc., USA
SO PCT Int. Appl., 608 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 2000024782 | A2 | 20000504 | WO 1999-US25044 | 19991025 |

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1998-105371 19981023
US 1999-428082 19991022

L9 ANSWER 5 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 2000:171099 CAPLUS
DN 132:212676
TI Compositions containing nucleic acids and ligands for therapeutic treatment
IN Baird, J. Andrew; Chandler, Lois Ann; Sosnowski, Barbara A.
PA Selective Genetics, Inc., USA
SO U.S., 131 pp., Cont.-in-part of U.S. Ser. No. 441,979, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 4

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI US 6037329 | A | 20000314 | US 1996-718904 | 19960924 |
| CA 2221269 | AA | 19961121 | CA 1996-2221269 | 19960516 |
| WO 9636362 | A1 | 19961121 | WO 1996-US7164 | 19960516 |

W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML

| | | | | |
|---|---|---|---|---|
| AU 9658628 | A1 | 19961129 | AU 1996-58628 | 19960516 |
| AU 710309 | B2 | 19990916 | | |
| EP 833665 | A1 | 19980408 | EP 1996-920274 | 19960516 |

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI

| | | | | |
|---|---|---|---|---|
| JP 11505805 | T2 | 19990525 | JP 1996-535090 | 19960516 |

PRAI US 1994-213446 19940315
US 1994-213447 19940315
US 1994-297961 19940829

US 1994-305771 19940913
US 1995-441979 19950516
WO 1996-US7164 19960516
RE.CNT 48
RE
(2) Anon; WO 9012597 1990 CAPLUS
(3) Anon; WO 9118012 1991 CAPLUS
(4) Anon; WO 9204918 1992 CAPLUS
(5) Anon; WO 9317669 1993 CAPLUS
(6) Anon; WO 9325688 1993 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 2000:98600 CAPLUS
DN 132:161230
TI **Inhibitors** of HIV membrane fusion, and identification method
IN Eckert, Debra M.; Chan, David C.; Malashkevich, Vladimir; Carr, Peter A.; Kim, Peter S.
PA Whitehead Institute for Biomedical Research, USA
SO PCT Int. Appl., 147 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 2000006599 | A1 | 20000210 | WO 1999-US17351 | 19990730 |

W: CA, JP, US
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRAI US 1998-94676 19980730
US 1998-100265 19980914
US 1998-101058 19980918
US 1999-132295 19990503
OS MARPAT 132:161230
RE.CNT 5
RE
(1) Chan, D; PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA 1998, V95, P1513
(2) Eckert, D; CELL 1999, V99, P103 CAPLUS
(3) Judice, J; PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA 1997, V94, P13426 CAPLUS
(4) Univ Duke; WO 9402505 A 1994
(5) Weissenhorn, W; PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA 1997, V94, P6065 CAPLUS

L9 ANSWER 7 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 1999:819270 CAPLUS
DN 132:69369
TI Compositions and methods for delivery of agents for altering neuronal growth, regeneration, and survival
IN Baird, Andrew; Berry, Martin; Logan, Ann; Gonzalez, Ana Maria
PA Selective Genetics, Inc., USA
SO PCT Int. Appl., 128 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 9966959 | A2 | 19991229 | WO 1999-US12126 | 19990601 |
| | WO 9966959 | A3 | 20000504 | | |

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,

TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9962380 A1 20000110 AU 1999-62380 19990601
PRAI US 1998-88419 19980601
US 1998-178286 19981023
WO 1999-US12126 19990601

L9 ANSWER 8 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 1999:736736 CAPLUS
DN 131:346503
TI Peptides derived from frameshift-mutated genes which elicit T cell immunity and their use as cancer vaccines
IN Gaudernack, Gustav; Eriksen, Jon Amund; Moller, Mona; Gjertsen, Marianne Klemp; Saeterdal, Ingvil
PA Norsk Hydro Asa, Norway
SO PCT Int. Appl., 167 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 9958552 | A2 | 19991118 | WO 1999-NO143 | 19990503 |
| WO 9958552 | A3 | 20000302 | | |

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

NO 9802097 A 19991109 NO 1998-2097 19980508
AU 9954516 A1 19991129 AU 1999-54516 19990503
PRAI NO 1998-2097 19980508
WO 1999-NO143 19990503

L9 ANSWER 9 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 1999:673065 CAPLUS
DN 131:318568
TI Chimeric protease comprising human subtilisin fragment(s), and uses thereof for pharmaceutical applications and for reducing the allergenicity of non-human proteases
IN Estell, David
PA Genencor International, Inc., USA
SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 9953078 | A2 | 19991021 | WO 1999-US8177 | 19990415 |
| WO 9953078 | A3 | 20000420 | | |

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,

ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9936432 A1 19991101 AU 1999-36432 19990415

PRAI US 1998-60854 19980415

WO 1999-US8177 19990415

L9 ANSWER 10 OF 26 CAPLUS COPYRIGHT 2000 ACS

AN 1999:502773 CAPLUS

DN 131:139482

TI Methods to identify immunomodulators using cognate interaction of PKC-.theta.

IN Vasquez, Nicki J.; Ron, Dorit; Voronova, Anna F.; Napolitano, Eugene W.

PA Terrapin Technologies, Inc., USA

SO U.S., 67 pp.
CODEN: USXXAM

DT Patent

LA English

FAN.CNT 6

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | US 5935803 | A | 19990810 | US 1996-665647 | 19960618 |
| | US 5519003 | A | 19960521 | US 1994-190802 | 19940201 |
| | US 5783405 | A | 19980721 | US 1995-541964 | 19951010 |
| | US 5776716 | A | 19980707 | US 1996-594447 | 19960131 |
| | CA 2233313 | AA | 19970417 | CA 1996-2233313 | 19961010 |
| | WO 9714038 | A1 | 19970417 | WO 1996-US16195 | 19961010 |
| | W: AU, CA, JP | | | | |
| | RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| | AU 9673986 | A1 | 19970430 | AU 1996-73986 | 19961010 |
| | EP 882228 | A1 | 19981209 | EP 1996-936307 | 19961010 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| | JP 2000500964 | T2 | 20000202 | JP 1997-515169 | 19961010 |
| | US 6054286 | A | 20000425 | US 1999-232130 | 19990115 |

PRAI US 1994-190802 19940201
US 1995-473089 19950607
US 1995-477346 19950607
US 1995-541964 19951010
US 1996-594447 19960131
US 1995-487072 19950607
US 1996-665647 19960618
WO 1996-US16195 19961010

RE.CNT 24

RE

(1) Anon; WO 9521252 1995 CAPLUS
(3) Dynlacht, B; Nature 1993, V363, P176 CAPLUS
(4) Fields; US 5283173 1994 CAPLUS
(5) Fong, H; Proc Natl Acad Sci USA 1986, V83, P2162 CAPLUS
(6) Guillemot, F; Proc Natl Acad Sci USA 1989, V86, P4594 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 11 OF 26 CAPLUS COPYRIGHT 2000 ACS

AN 1999:443132 CAPLUS

DN 131:208594

TI Identification of oligopeptide sequences which inhibit migration induced by a wide range of chemokines

AU Reckless, Jill; Grainger, David J.

CS Department of Medicine, Addenbrookes Hospital, University of Cambridge, Cambridge, CB2 2QQ, UK

SO Biochem. J. (1999), 340(3), 803-811
CODEN: BIJOAK; ISSN: 0264-6021

PB Portland Press Ltd.

DT Journal

LA English

RE.CNT 32

RE
(1) Ahuja, S; Immunol Today 1994, V15, P281 CAPLUS
(2) Bleul, C; Nature (London) 1996, V382, P829 CAPLUS
(3) Brown, Z; J Leukocyte Biol 1996, V59, P75 CAPLUS
(4) Cocchi, F; Science 1995, V270, P1811 CAPLUS
(5) Conti, P; Blood 1997, V89, P4120 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 12 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 1999:194178 CAPLUS
DN 130:236476
TI Chemokine-derived peptides, peptide variants, derivatives and analogs for modulation of inflammatory responses
IN Grainger, David J.; Tatalick, Lauren Marie; Kanaly, Suzanne T.
PA Neorx Corporation, USA
SO PCT Int. Appl., 208 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 9912968 | A2 | 19990318 | WO 1998-US19052 | 19980911 |
| | WO 9912968 | A3 | 19990729 | | |
| | W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 9893153 | A1 | 19990329 | AU 1998-93153 | 19980911 |
| | EP 1012187 | A2 | 20000628 | EP 1998-946057 | 19980911 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| PRAI | US 1997-927939 | 19970911 | | | |
| | WO 1998-US19052 | 19980911 | | | |

L9 ANSWER 13 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 1999:147365 CAPLUS
DN 130:205126
TI Mimotopes and anti-mimotopes of human platelet glycoprotein Ib/IX
IN Miller, Jonathan L.; Lyle, Vicki A.
PA The Research Foundation of State University of New York, USA
SO U.S., 52 pp., Cont.-in-part of U.S. Ser. No. 406,330.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | US 5877155 | A | 19990302 | US 1995-556597 | 19951113 |
| | US 5817748 | A | 19981006 | US 1995-406330 | 19950317 |
| | WO 9718236 | A1 | 19970522 | WO 1996-US17882 | 19961108 |
| | W: CA, CN, JP | | | | |
| | RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| | EP 876396 | A1 | 19981111 | EP 1996-942734 | 19961108 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| | CN 1202175 | A | 19981216 | CN 1996-198270 | 19961108 |
| PRAI | US 1995-406330 | 19950317 | | | |
| | US 1995-556597 | 19951113 | | | |
| | WO 1996-US17882 | 19961108 | | | |

RE.CNT 29

RE
(1) Anon; WO 9109614 1991 CAPLUS
(2) Anon; WO 9209302 1992 CAPLUS
(3) Balass, M; Proc Natl Acad Sci USA 1993, V90, P10638 CAPLUS
(5) Christian, R; J Mol Biol 1992, V227, P711 CAPLUS
(6) Collen, D; Thrombosis and Haemostasis 1994, V71(1), P95 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 14 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 1999:2009 CAPLUS
DN 130:206600
TI Investigation of S-farnesyl transferase substrate specificity with combinatorial tetrapeptide libraries
AU Boutin, Jean A.; Marande, William; Petit, Laurence; Loynel, Armelle; Desmet, Christine; Canet, Emmanuel; Fauchere, Jean-Luc
CS Department of Peptides, Institut de Recherches Servier, Suresnes, 92150, Fr.
SO Cell. Signalling (1998), Volume Date 1999, 11(1), 59-69
CODEN: CESIEY; ISSN: 0898-6568
PB Elsevier Science Inc.
DT Journal
LA English
RE.CNT 52
RE
(1) Armstrong, S; J Biol Chem 1995, V270, P7864 CAPLUS
(2) Boutin, J; Anal Biochem 1996, V234, P126 CAPLUS
(3) Boutin, J; Arch Biochem Biophys 1998, V354, P83 CAPLUS
(4) Boutin, J; Cell Signal 1997, V9, P15 CAPLUS
(5) Boutin, J; Eur J Biochem 1993, V214, P853 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 15 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 1996:683254 CAPLUS
DN 125:321431
TI A novel src- and ras-suppressed protein kinase C substrate associated with cytoskeletal architecture
AU Lin, Xueying; Tombler, Eugene; Nelson, Peter J.; Ross, Michael; Gelman, Irwin H.
CS Dep. Microbiol., Mount Sinai Sch. Med., New York, NY, 10029, USA
SO J. Biol. Chem. (1996), 271(45), 28430-28438
CODEN: JBCHA3; ISSN: 0021-9258
DT Journal
LA English

L9 ANSWER 16 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 1996:596136 CAPLUS
DN 125:257215
TI Cloning and formulation of antiobesity proteins
IN Basinski, Margaret B.; Dimarchi, Richard D.; Heath, William F.,Jr.; Schoner, Brigitte E.
PA Lilly, Eli, and Co., USA
SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 10

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 9623513 | A1 | 19960808 | WO 1996-US946 | 19960129 |
| | W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI | | | | |
| | RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, | | | | |

NE, SN, TD, TG

| | | | | |
|---|---|---|---|---|
| US 5552524 | A | 19960903 | US 1995-384292 | 19950206 |
| AU 9647659 | A1 | 19960821 | AU 1996-47659 | 19960129 |
| EP 810871 | A1 | 19971210 | EP 1996-903647 | 19960129 |

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE

PRAI US 1995-381661 19950131
US 1995-384292 19950206
US 1995-381037 19950131
US 1995-381049 19950131
US 1995-381054 19950131
US 1995-381163 19950131
US 1995-381666 19950131
US 1995-383632 19950206
US 1995-383649 19950206
US 1995-383650 19950206
US 1995-384492 19950206
WO 1996-US946 19960129

OS MARPAT 125:257215

L9 ANSWER 17 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 1996:596134 CAPLUS
DN 125:257213
TI Cloning and formulation of antiobesity proteins
IN Basinski, Margaret B.; Dimarchi, Richard D.; Heath, William F., Jr.; Schoner, Brigitte E.
PA Lilly, Eli, and Co., USA
SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 9623518 | A1 | 19960808 | WO 1996-US1345 | 19960129 |

W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI

RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE

| | | | | |
|---|---|---|---|---|
| US 5559208 | A | 19960924 | US 1995-383639 | 19950206 |
| AU 9648620 | A1 | 19960821 | AU 1996-48620 | 19960129 |
| EP 809508 | A1 | 19971203 | EP 1996-904542 | 19960129 |

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE

PRAI US 1995-381031 19950131
US 1995-383639 19950206
WO 1996-US1345 19960129

OS MARPAT 125:257213

L9 ANSWER 18 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 1996:596133 CAPLUS
DN 125:257212
TI Cloning and formulation of antiobesity proteins
IN Basinski, Margaret B.; Dimarchi, Richad D.; Heath, William F., Jr.; Schoner, Brigitte E.
PA Lilly, Eli, and Co., USA
SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 9623519 | A1 | 19960808 | WO 1996-US1412 | 19960129 |

W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE,

ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE

| | | | | |
|---|---|---|---|---|
| US 5552523 | A | 19960903 | US 1995-384183 | 19950206 |
| AU 9647744 | A1 | 19960821 | AU 1996-47744 | 19960129 |
| EP 810872 | A1 | 19971210 | EP 1996-903766 | 19960129 |

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE

PRAI US 1995-381458 19950131
US 1995-384183 19950206
WO 1996-US1412 19960129
OS MARPAT 125:257212

L9 ANSWER 19 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 1996:435271 CAPLUS
DN 125:78553
TI High level expression and facile purification of proteins, peptides and conjugates for immunization, purification and detection applications
IN Knuth, Mark W.; Haak-Frendscho, Mary; Shultz, John W.; Lesley, Scott A.; Villars, Catherine E.
PA Promega Corporation, USA
SO PCT Int. Appl., 120 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 9615249 | A1 | 19960523 | WO 1995-US14518 | 19951113 |

W: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

| | | | | |
|---|---|---|---|---|
| US 6069230 | A | 20000530 | US 1994-338382 | 19941110 |
| CA 2204914 | AA | 19960523 | CA 1995-2204914 | 19951113 |
| AU 9644623 | A1 | 19960606 | AU 1996-44623 | 19951113 |
| AU 707030 | B2 | 19990701 | | |
| EP 791068 | A1 | 19970827 | EP 1995-943330 | 19951113 |

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE

| | | | | |
|---|---|---|---|---|
| JP 10509038 | T2 | 19980908 | JP 1995-516180 | 19951113 |
| US 5989554 | A | 19991123 | US 1998-174060 | 19981016 |

PRAI US 1994-338382 19941110
WO 1995-US14518 19951113

L9 ANSWER 20 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 1995:880366 CAPLUS
DN 123:279695
TI C2 region-derived peptides inhibit translocation and function of .beta. protein kinase C in vivo
AU Ron, Dorit; Luo, Jianhua; Mochly-Rosen, Daria
CS Dep. Molecular Pharmacology, Stanford Univ., Stanford, CA, 94305-5332, USA
SO J. Biol. Chem. (1995), 270(41), 24180-7
CODEN: JBCHA3; ISSN: 0021-9258
DT Journal
LA English

L9 ANSWER 21 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 1995:842649 CAPLUS
DN 123:246823

TI Hydrophilic signal oligopeptides and methods of therapeutic use
IN Rath, Matthias
PA USA
SO PCT Int. Appl., 87 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 9519568 | A1 | 19950720 | WO 1995-US575 | 19950112 |
| | W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN | | | | |
| | RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | AU 9516810 | A1 | 19950801 | AU 1995-16810 | 19950112 |
| | EP 744027 | A1 | 19961127 | EP 1995-908522 | 19950112 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE | | | | |
| | AU 9881834 | A1 | 19981008 | AU 1998-81834 | 19980824 |
| PRAI | US 1994-182248 | 19940114 | | | |
| | WO 1995-US575 | 19950112 | | | |

L9 ANSWER 22 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 1995:538212 CAPLUS
DN 122:291534
TI Preparation of peptide amides having smooth muscle relaxant activity as vasoactive intestinal polypeptide (VIP) analogs
IN Kishida, Tatsu; Konno, Fukio; Kawamoto, Takafumi; Kimura, Hitoshi; Osada, Naomi
PA Daicel Chem, Japan; Meiji Seika Co
SO Jpn. Kokai Tokkyo Koho, 29 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | JP 06092991 | A2 | 19940405 | JP 1991-34335 | 19910228 |
| OS | MARPAT 122:291534 | | | | |

L9 ANSWER 23 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 1994:321360 CAPLUS
DN 120:321360
TI Immunoreactive peptides from Epstein-Barr virus (EBV)
IN Smith, Richard S.; Pearson, Gary R.; Parks, Elliot D.
PA Johnson and Johnson, USA
SO PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 9406470 | A1 | 19940331 | WO 1993-US8699 | 19930915 |
| | W: AU, CA, JP, US | | | | |
| | RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| | EP 671946 | A1 | 19950920 | EP 1993-921588 | 19930915 |
| | EP 671946 | B1 | 20000830 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE | | | | |
| | JP 08510714 | T2 | 19961112 | JP 1993-508271 | 19930915 |
| | AU 693421 | B2 | 19980702 | AU 1993-49227 | 19930915 |

EP 889052 A2 19990107 EP 1998-113827 19930915
EP 889052 A3 19990818
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE
PRAI US 1992-945280 19920915
EP 1993-921588 19930915
WO 1993-US8699 19930915

L9 ANSWER 24 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 1992:440432 CAPLUS
DN 117:40432
TI Novel immunosuppressant peptides
IN Gaeta, Federico C. A.; Powell, Michael F.; Grey, Howard M.; Sette, Alessandro D.; Arrhenius, Thomas S.
PA Cytel Corp., USA; Sandoz A.-G.; Sandoz-Patent-G.m.b.H.
SO PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 9202543 | A1 | 19920220 | WO 1991-EP1420 | 19910729 |
| W: AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MC, MG, MW, NO, PL, RO, SD, SU, US | | | | |
| RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, ML, MR, NL, SE, SN, TD, TG | | | | |
| AU 9183054 | A1 | 19920302 | AU 1991-83054 | 19910729 |
| ZA 9106072 | A | 19930428 | ZA 1991-6072 | 19910801 |
| US 5679640 | A | 19971021 | US 1995-400781 | 19950308 |

PRAI US 1990-560615 19900801
US 1991-654482 19910212
WO 1991-EP1420 19910729
US 1993-143973 19931027
OS MARPAT 117:40432

L9 ANSWER 25 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 1992:99302 CAPLUS
DN 116:99302
TI Cell-cycle-dependent regulation of phosphorylation of human retinoblastoma gene product
IN Fung, Yuen Kai
PA Research Development Foundation, USA
SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 9109114 | A1 | 19910627 | WO 1990-US7216 | 19901207 |
| W: AU, CA, DK, FI, JP, KR, NO, SU, US | | | | |
| RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE | | | | |
| ZA 9009755 | A | 19910925 | ZA 1990-9755 | 19901205 |
| IL 96575 | A1 | 19950526 | IL 1990-96575 | 19901206 |
| CA 2070660 | AA | 19910608 | CA 1990-2070660 | 19901207 |
| CN 1052607 | A | 19910703 | CN 1990-109950 | 19901207 |
| AU 9170389 | A1 | 19910718 | AU 1991-70389 | 19901207 |
| AU 653142 | B2 | 19940922 | | |
| EP 504289 | A1 | 19920923 | EP 1991-901398 | 19901207 |
| EP 504289 | B1 | 19990915 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE | | | | |
| AT 184653 | E | 19991015 | AT 1991-901398 | 19901207 |
| ES 2135390 | T3 | 19991101 | ES 1991-901398 | 19901207 |
| NO 9202168 | A | 19920715 | NO 1992-2168 | 19920601 |

FI 9202615 A 19920605 FI 1992-2615 19920605
PRAI US 1989-447282 19891207
WO 1990-US7216 19901207

L9 ANSWER 26 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 1989:400067 CAPLUS
DN 111:67
TI Use of the membrane invasion culture system (MICS) as a screen for anti-invasive agents
AU Welch, Danny R.; Lobl, Thomas J.; Seftor, Elisabeth A.; Wack, Peter J.; Aeed, Paul A.; Yohem, Karin H.; Seftor, Richard E. B.; Hendrix, Mary J.
C.
CS Dep. Cancer Infect. Dis. Res., Upjohn Co., Kalamazoo, MI, USA
SO Int. J. Cancer (1989), 43(3), 449-57
CODEN: IJCNAW; ISSN: 0020-7136
DT Journal
LA English